Resultado de AGM
Renk AG
n / a
07:46 20/03/24
11 April 2024 1730 BST
Results of Annual General Meeting held on 11 April 2024
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 11 - 14 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
| Resolución | Votos a favor | % de votos emitidos | Votos en contra | % de votos emitidos | Votos emitidos en total | Total de votos emitidos como% del capital social emitido | Votos retenidos |
1 | To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2023 | 1,205,690,871 | 99.88 | 1,470,816 | 0.12 | 1,207,161,687 | 77.87% | 9,700,968 |
2 | To confirm dividends | 1,215,177,590 | 99.94 | 790,189 | 0.06 | 1,215,967,779 | 78.44% | 894,978 |
3 | To reappoint PricewaterhouseCoopers LLP as Auditor | 1,208,377,872 | 99.36 | 7,843,545 | 0.64 | 1,216,221,417 | 78.45% | 642,048 |
4 | To authorise the Directors to agree the remuneration of the Auditor | 1,215,717,786 | 99.98 | 279,816 | 0.02 | 1,215,997,602 | 78.44% | 722,222 |
5a | To re-elect Michel Demaré as a Director | 1,197,325,871 | 98.49 | 18,416,788 | 1.51 | 1,215,742,659 | 78.42% | 1,120,559 |
5b | To re-elect Pascal Soriot as a Director | 1,206,729,787 | 99.26 | 9,036,742 | 0.74 | 1,215,766,529 | 78.42% | 1,098,706 |
5c | To re-elect Aradhana Sarin as a Director | 1,212,225,383 | 99.71 | 3,509,122 | 0.29 | 1,215,734,505 | 78.42% | 1,129,532 |
5d | To re-elect Philip Broadley as a Director | 1,197,937,103 | 98.54 | 17,773,671 | 1.46 | 1,215,710,774 | 78.42% | 1,153,360 |
5e | To re-elect Euan Ashley as a Director | 1,213,332,278 | 99.80 | 2,375,199 | 0.20 | 1,215,707,477 | 78.42% | 1,156,567 |
5f | To re-elect Deborah DiSanzo as a Director | 1,215,396,504 | 99.97 | 318,525 | 0.03 | 1,215,715,029 | 78.42% | 1,149,106 |
5g | To re-elect Diana Layfield as a Director | 1,215,424,019 | 99.98 | 292,514 | 0.02 | 1,215,716,533 | 78.42% | 1,147,602 |
5h | To elect Anna Manz as a Director | 1,215,297,866 | 99.97 | 417,067 | 0.03 | 1,215,714,933 | 78.42% | 1,149,091 |
5i | To re-elect Sheri McCoy as a Director | 1,158,846,767 | 95.32 | 56,874,293 | 4.68 | 1,215,721,060 | 78.42% | 1,142,920 |
5j | To re-elect Tony Mok as a Director | 1,215,346,936 | 99.97 | 346,157 | 0.03 | 1,215,693,093 | 78.42% | 1,170,931 |
5k | To re-elect Nazneen Rahman as a Director | 1,191,449,316 | 98.59 | 16,988,178 | 1.41 | 1,208,437,494 | 77.95% | 8,426,242 |
5l | To re-elect Andreas Rummelt as a Director | 1,215,395,253 | 99.97 | 314,359 | 0.03 | 1,215,709,612 | 78.42% | 1,154,412 |
5m | To re-elect Marcus Wallenberg as a Director | 947,479,100 | 77.93 | 268,252,536 | 22.07 | 1,215,731,636 | 78.42% | 1,132,416 |
6 | To approve the Annual Report on Remuneration for the year ended 31 December 2023 | 1,158,470,360 | 95.32 | 56,835,406 | 4.68 | 1,215,305,766 | 78.40% | 1,558,941 |
7 | Aprobar la Política de Retribuciones de los Consejeros
| 761,702,826 | 64.43 | 420,514,520 | 35.57 | 1,182,217,346 | 76.26% | 34,645,873 |
8 | To approve amendments to the AstraZeneca Performance Share Plan 2020
| 769,577,451 | 65.34 | 408,204,003 | 34.66 | 1,177,781,454 | 75.97% | 39,083,170 |
9 | To authorise limited political donations | 1,184,223,861 | 98.00 | 24,219,787 | 2.00 | 1,208,443,648 | 77.95% | 8,278,265 |
10 | Autorizar a los Consejeros a adjudicar acciones. | 1,129,625,915 | 92.94 | 85,836,406 | 7.06 | 1,215,462,321 | 78.41% | 1,259,562 |
11 | Autorizar a los Consejeros a no aplicar los derechos de tanteo. | 1,044,559,011 | 85.95 | 170,708,848 | 14.05 | 1,215,267,859 | 78.39% | 1,454,048 |
12 | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments | 997,629,834 | 82.33 | 214,143,713 | 17.67 | 1,211,773,547 | 78.17% | 4,948,031 |
13 | Autorizar a la Compañía a comprar sus propias acciones. | 1,205,828,976 | 99.23 | 9,306,860 | 0.77 | 1,215,135,836 | 78.38% | 1,585,923 |
14 | Reducir el plazo de convocatoria de las juntas generales | 1,131,157,449 | 93.07 | 84,269,754 | 6.93 | 1,215,427,203 | 78.40% | 1,294,801 |
A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Statement in connection with resolutions 5m, 7 and 8
AstraZeneca is pleased that all resolutions were supported at today's Annual General Meeting. In particular, the Board thanks the majority of our shareholders who have supported the Remuneration Policy (the Policy) and will continue to engage with our shareholders and the proxy advisors to explain our need for global benchmarks and pay for performance, which is driven by the Policy.
We will publish an update on the engagement with shareholders on resolutions 5m, 7 and 8 and on any action taken as a result within six months of today's AGM, in accordance with the UK Corporate Governance Code.
Capital emitido
As at 9 April 2024, the number of issued shares of the Company was 1,550,231,084 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
AstraZeneca
AstraZeneca (LSE / STO / Nasdaq: AZN) es una empresa biofarmacéutica mundial dirigida por la ciencia que se centra en el descubrimiento, el desarrollo y la comercialización de medicamentos recetados en oncología, enfermedades raras y biofarmacéuticos, incluidos los de enfermedades cardiovasculares, renales y metabólicas y respiratorias. E inmunología. Con sede en Cambridge, Reino Unido, AstraZeneca opera en más de 100 países y sus medicamentos innovadores son utilizados por millones de pacientes en todo el mundo. Por favor visita astrazeneca.com y sigue a la Compañía en las redes sociales @AstraZeneca.
Contacto
Para obtener detalles sobre cómo ponerse en contacto con el equipo de relaciones con inversores, haga clic en esta página. Para contactos de medios, haga clic en esta página.
Adrián Kemp
Secretaria de Empresa
AstraZenecaPLC
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.